Spotlight Pathology

Spotlight Pathology, a University of Manchester spin‑out developing AI‑powered tools for blood cancer diagnostics, has secured £1.5 million in VC funding co‑led by Liverpool City Region Seed Fund and UKI2S, with continued support from existing investors including Deepbridge, Lyva Labs, EHE Ventures and River Capital.

Summary of transaction details:

• Value: £1.5 million
• Sector: Healthcare & Biotech
• Advisor: Not disclosed
• Key Entities: Target – Spotlight Pathology; Lead Investors – Liverpool City Region Seed Fund, UKI2S
• Location: Sci‑Tech Daresbury, Cheshire, UK

Note: The funding will accelerate the commercial rollout of Spotlight Pathology’s lymphoma diagnostic AI device, reflecting strong investor confidence in UK health‑tech innovation and the company’s growth trajectory within the NHS and private pathology markets.